Abstract 47P
Background
Ophthalmic metastases are less common than metastases in other body parts. Breast cancer, the leading cancer in women, is the most frequent primary tumor in these cases. Due to its rarity, few studies have reviewed the efficacy of radiotherapy for these metastases. This study aims to evaluate the response and side effects of radiation therapy in ophthalmic metastases from breast cancer.
Methods
We searched MEDLINE, NCBI, Europe PMC, Science Direct, and Google Scholar with relevant keywords related to radiotherapy, ocular metastases, and breast cancer. Prospective, retrospective studies and case reports from 2000 to 2024 that report the use of radiotherapy for local treatment of ocular or periocular metastases of breast cancer patients were included. The study quality was assessed using the Newcastle Ottawa Scale (NOS) for cohort studies and Joanna Briggs Institute’s (JBI) for case reports.
Results
We included 15 studies (12 case reports, 3 retrospective) with 113 breast cancer patients. Most had unilateral metastases to the eye (71.68%), with vision impairment as the most common symptom (41.61%). The time from primary tumor diagnosis to ocular metastases ranged from 0-245 months. The cumulative dose of radiation given was 20-60Gy, divided into 3-22 fractions of 1.8 to 3 Gy each, yielding a 68.18% complete/partial response rate. The most common side effects are dry eyes (56.41%) and keratoconjunctivitis (15.38%), while radiation keratopathy and retinopathy were less frequent (5.13% and 3.85%, respectively).
Conclusions
Radiotherapy is a viable option for treating ocular metastases from breast cancer, with a favorable response rate and minimal severe side effects. The variation in dosages applied in different cases suggests a relatively broad therapeutic window.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Charista.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.